Ashvattha announced the formation of a Scientific Advisory Board. The SAB will work closely with Ashvattha’s management team to select and develop highly differentiated HDTs to treat diseases with significant unmet medical need.
Ashvattha announced results from a preclinical study demonstrating the successful localization of HDs to target sites of inflammation in arthritic tissues at the ACR Convergence 2020, held virtually November 5-9, 2020.
Ashvattha announced results from a preclinical study demonstrating targeting of HDs to renal macrophages after acute ischemia in a diabetic animal model, at the American Society of Nephrology (ASN) Kidney Week 2020, held virtually October 19-25, 2020.
Ashvattha Therapeutics announced the appointment of George G. Montgomery to its board of directors. Montgomery brings more than 30 years of extensive experience as an investor, entrepreneur and investment banker across diverse healthcare sectors.